Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-271P refers to a pseudogene of U6 small nuclear RNA (snRNA); pseudogenes are genomic loci that resemble functional genes but are generally non-functional due to mutations or lack of regulatory elements[2]. The canonical U6 small nuclear RNA (snRNA) is a highly conserved, non-coding RNA that is a crucial part of the spliceosome complex, responsible for the removal of introns from precursor mRNA in eukaryotic nuclei[1][3]. However, RNU6-271P is not a functional gene but rather a “dead” copy, or remnant, of an ancestral U6 snRNA gene[3]. It does not encode a protein, is not known to produce a functional RNA product, and has no established biological function or disease role. Pseudogenes like RNU6-271P are common in the genome and typically do not serve as therapeutic targets, biomarkers, or have known drug interactions[2][3]. In rare cases, some pseudogenes may be transcribed and play regulatory roles (e.g., acting as microRNA decoys)[2], but there is no evidence for RNU6-271P functionality. This entry likely reflects a gene annotation artifact or a misinterpretation as a drug target or receptor. Key clarifications: - RNU6-271P is a pseudogene, not an actual RNA, protein, receptor, enzyme, or clinically actionable target. - It is not involved in signal transduction, gene regulation, or any canonical biological pathway. - There is nothing to suggest it is a therapeutic or diagnostic target. - Calling this a receptor or molecular target is incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 271, pseudogene (RNU6-271P).